Liver Fibrosis Market Set to Grow Substantially Through 2034, DelveInsight Projects | Madrigal Pharma, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio

DelveInsight's "Liver Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Liver Fibrosis, historical and forecasted epidemiology as well as the Liver Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Liver Fibrosis, offering comprehensive insights into the Liver Fibrosis revenue trends, prevalence, and treatment landscape. The report delves into key Liver Fibrosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Liver Fibrosis therapies. Additionally, we cover the landscape of Liver Fibrosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Liver Fibrosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Liver Fibrosis space.

To Know in detail about the Liver Fibrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Liver Fibrosis Market Forecast
https://www.delveinsight.com/sample-request/liver-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Liver Fibrosis Market Report:
• The Liver Fibrosis market size was valued ~USD 1,800 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In January 2025, Alentis Therapeutics, a clinical-stage biotech company focused on developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced promising topline results from two clinical trials of lixudebart (ALE.F02), a monoclonal antibody designed to reverse organ fibrosis.
• In January 2025, Akero Therapeutics has released preliminary topline results from its Phase IIb SYMMETRY study, evaluating efruxifermin (EFX) in patients with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, caused by metabolic dysfunction-associated steatohepatitis (MASH). This placebo-controlled, multicenter, double-blind, dose-ranging, randomized trial included adult participants with the condition. The primary efficacy endpoint measured the proportion of patients achieving at least a one-stage fibrosis improvement by week 36 without MASH progression.
• In November 2024, Scottish biopharmaceutical firm Resolution Therapeutics secured approval from Spain's Agency of Medicines and Medical Products (AEMPS) to extend its Phase I/II EMERALD trial of RTX001, a regenerative macrophage therapy, into Spain. RTX001, the company's flagship product, is an engineered autologous regenerative macrophage therapy designed for individuals with end-stage liver disease.
• In November 2024, Novo Nordisk announced favorable results from the first part of the ESSENCE trial, evaluating semaglutide 2.4mg for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
• In 2023, the US Liver Fibrosis Treatment Market was valued at around USD 1,300 million and is expected to grow with the introduction of emerging therapies.
• In 2023, the Liver Fibrosis Treatment Market Size across the EU4 and the UK was estimated at around USD 400 million, accounting for approximately 23% of the total market revenue in the 7MM.
• In 2023, Germany led the Liver Fibrosis Treatment Market within the EU4 and the UK, contributing approximately USD 120 million. Italy ranked second with around USD 95 million, followed by the UK at roughly USD 75 million.
• In 2023, Japan's Liver Fibrosis Treatment Market was valued at approximately USD 80 million and is expected to grow throughout the forecast period (2025-2034).
• Projections indicate that REZDIFFRA (resmetirom) could reach an estimated market value of around USD 2,500 million in the 7MM by 2034.
• DelveInsight's epidemiology model estimates that in 2023, around 8 million diagnosed prevalent cases of liver fibrosis were recorded across the 7MM, with numbers expected to rise by 2034.
• In 2023, the US had the highest number of liver fibrosis cases among the 7MM, with around 4 million cases, projected to increase by 2034.
• In 2023, Germany recorded the highest number of liver fibrosis cases among the EU4 and the UK, with approximately 770,000 cases. Italy and France followed with around 620,000 and 520,000 cases, respectively, while Spain had the lowest, with approximately 360,000 cases.
• In Japan, during 2023, MASH/NASH cases were classified by severity into F0, F1, F2, F3, and F4 stages. The F1 stage had the highest prevalence, with approximately 240,000 cases, whereas the F4 stage had the lowest, with around 35,000 cases.
• Key Liver Fibrosis Companies: Madrigal Pharmaceuticals, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio, Beijing Continent Pharmaceutical, Gilead Sciences, Galmed R&D, Hepion Pharmaceuticals, HK inno.N Corporation, Conatus Pharmaceuticals, Dr. Falk Pharma GmbH, InterMune, Bristol-Myers Squibb, Merck Sharp & Dohme LLC, Akero Therapeutics, Inc, Pfizer, AstraZeneca, and others
• Key Liver Fibrosis Therapies: REZDIFFRA (resmetirom), Efruxifermin (EFX), Denifanstat (TVB-2640), Survodutide (BI 456906), Pegozafermin (BIO89-100), Hydronidone capsules, Simtuzumab, Aramchol, Rencofilstat, oltipraz, IDN-6556, ZED1227, interferon gamma-1b, BMS-986263, peginterferon alfa-2b (SCH 54031), Efruxifermin, PF-06865571, Zibotentan + dapagliflozin, and others
• The Liver Fibrosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Liver Fibrosis pipeline products will significantly revolutionize the Liver Fibrosis market dynamics.
• According to DelveInsight's assessment, the estimated total number of diagnosed prevalent cases of liver fibrosis in the 7MM was approximately 19 million in 2023.
• In 2023, the United States recorded the highest number of diagnosed prevalent cases of liver fibrosis, with 9 million cases, and this figure is expected to increase in the future.
• In 2023, Germany had the highest number of diagnosed prevalent cases of liver fibrosis among European countries, followed by Italy, while Spain had the fewest cases.
• In 2023, Japan had around 2 million diagnosed prevalent cases of liver fibrosis, representing approximately 12% of the total cases in the 7MM.
• In the US, individuals in the F1 stage of NASH were most impacted by liver fibrosis, with approximately 3 million cases reported in 2023, based on severity-specific diagnosed prevalent cases.
• In 2023, the total diagnosed prevalent cases of NASH-related liver fibrosis in the EU4 and the UK were approximately 1 million.

Liver Fibrosis Overview
Liver fibrosis is the excessive accumulation of extracellular matrix proteins, including collagen, in the liver, resulting from chronic liver damage. It occurs when the liver attempts to repair itself after prolonged inflammation or injury caused by conditions such as hepatitis, alcohol abuse, or fatty liver disease. Over time, fibrosis can lead to the scarring of liver tissue, potentially progressing to cirrhosis, which impairs liver function. Early-stage fibrosis is often reversible if the underlying cause is treated, but advanced stages may cause significant liver damage.

Get a Free sample for the Liver Fibrosis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/liver-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Liver Fibrosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Liver Fibrosis Epidemiology Segmentation:
The Liver Fibrosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Liver Fibrosis
• Prevalent Cases of Liver Fibrosis by severity
• Gender-specific Prevalence of Liver Fibrosis
• Diagnosed Cases of Episodic and Chronic Liver Fibrosis

Download the report to understand which factors are driving Liver Fibrosis epidemiology trends @ Liver Fibrosis Epidemiology Forecast
https://www.delveinsight.com/sample-request/liver-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Liver Fibrosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Liver Fibrosis market or expected to get launched during the study period. The analysis covers Liver Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on
market share.
The report also covers the Liver Fibrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Liver Fibrosis Therapies and Key Companies
• REZDIFFRA (resmetirom): Madrigal Pharmaceuticals
• Efruxifermin (EFX): Akero Therapeutics
• Denifanstat (TVB-2640): Sagimet Biosciences
• Survodutide (BI 456906): Boehringer Ingelheim/Zealand Pharma
• Pegozafermin (BIO89-100): 89bio
• Hydronidone capsules: Beijing Continent Pharmaceutical
• Simtuzumab: Gilead Sciences
• Aramchol: Galmed R&D
• Rencofilstat: Hepion Pharmaceuticals
• oltipraz: HK inno.N Corporation
• IDN-6556: Conatus Pharmaceuticals
• ZED1227: Dr. Falk Pharma GmbH
• interferon gamma-1b: InterMune
• BMS-986263: Bristol-Myers Squibb
• peginterferon alfa-2b (SCH 54031): Merck Sharp & Dohme LLC
• Efruxifermin: Akero Therapeutics, Inc
• PF-06865571: Pfizer
• Zibotentan + dapagliflozin: AstraZeneca

Discover more about therapies set to grab major Liver Fibrosis market share @ Liver Fibrosis Treatment Landscape
https://www.delveinsight.com/sample-request/liver-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Liver Fibrosis Market Drivers
• Rising Prevalence of Chronic Liver Diseases
• Advancements in Diagnostic Techniques
• Ongoing Drug Development
• Awareness Programs
• Government Initiatives

Liver Fibrosis Market Barriers
• High Treatment Costs
• Lack of Approved Therapies
• Slow Diagnosis in Early Stages
• Regulatory Challenges
• Patient Adherence Issues

Scope of the Liver Fibrosis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Liver Fibrosis Companies: Madrigal Pharmaceuticals, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio, Beijing Continent Pharmaceutical, Gilead Sciences, Galmed R&D, Hepion Pharmaceuticals, HK inno.N Corporation, Conatus Pharmaceuticals, Dr. Falk Pharma GmbH, InterMune, Bristol-Myers Squibb, Merck Sharp & Dohme LLC, Akero Therapeutics, Inc, Pfizer, AstraZeneca, and others
• Key Liver Fibrosis Therapies: REZDIFFRA (resmetirom), Efruxifermin (EFX), Denifanstat (TVB-2640), Survodutide (BI 456906), Pegozafermin (BIO89-100), Hydronidone capsules, Simtuzumab, Aramchol, Rencofilstat, oltipraz, IDN-6556, ZED1227, interferon gamma-1b, BMS-986263, peginterferon alfa-2b (SCH 54031), Efruxifermin, PF-06865571, Zibotentan + dapagliflozin, and others
• Liver Fibrosis Therapeutic Assessment: Liver Fibrosis current marketed and Liver Fibrosis emerging therapies
• Liver Fibrosis Market Dynamics: Liver Fibrosis market drivers and Liver Fibrosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Liver Fibrosis Unmet Needs, KOL's views, Analyst's views, Liver Fibrosis Market Access and Reimbursement

To know more about Liver Fibrosis companies working in the treatment market, visit @ Liver Fibrosis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/liver-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Liver Fibrosis Market Report Introduction
2. Executive Summary for Liver Fibrosis
3. SWOT analysis of Liver Fibrosis
4. Liver Fibrosis Patient Share (%) Overview at a Glance
5. Liver Fibrosis Market Overview at a Glance
6. Liver Fibrosis Disease Background and Overview
7. Liver Fibrosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Liver Fibrosis
9. Liver Fibrosis Current Treatment and Medical Practices
10. Liver Fibrosis Unmet Needs
11. Liver Fibrosis Emerging Therapies
12. Liver Fibrosis Market Outlook
13. Country-Wise Liver Fibrosis Market Analysis (2020-2034)
14. Liver Fibrosis Market Access and Reimbursement of Therapies
15. Liver Fibrosis Market Drivers
16. Liver Fibrosis Market Barriers
17. Liver Fibrosis Appendix
18. Liver Fibrosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Liver Fibrosis Pipeline https://www.delveinsight.com/report-store/liver-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Liver Fibrosis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Liver Fibrosis market. A detailed picture of the Liver Fibrosis pipeline landscape is provided, which includes the disease overview and Liver Fibrosis treatment guidelines.

Liver Fibrosis Epidemiology https://www.delveinsight.com/report-store/liver-fibrosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Liver Fibrosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Liver Fibrosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Sglt2 Inhibitors Market: https://www.delveinsight.com/report-store/sglt2-inhibitors-market
• Electroencephelographs Pipeline Insight: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight
• Fabry Disease Market: https://www.delveinsight.com/report-store/fabry-disease-market
• Dental Implants And Prosthesis Market: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.